Argenica Therapeutics Ltd (AU:AGN) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Argenica Therapeutics is making significant progress in its Phase 2 trial for acute ischaemic stroke, having dosed 80% of its target patients. The trial, which is on track to complete by mid-2025, is showing positive feedback with no reported issues. Argenica is also preparing to submit an Investigational New Drug application to the FDA, paving the way for future trials in the U.S.
For further insights into AU:AGN stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Can Super Micro Computer Stock Rebound to $60? Here’s What This Analyst Expects
- C3.ai Stock Wins a New Street-High Price Target
- ‘A Strong Year Is Coming,’ Says Top Analyst About AMD Stock
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
